Technical Data

V2115-26C
Clone Type
Polyclonal
Host
Rabbit
Source
Rat
Isotype
IgG
Grade
Affinity Purified
Applications
E
Crossreactivity
Rt
Shipping Temp
Blue Ice
Storage Temp
-20°C
Rabbit Anti-Vasoactive intestinal Polypeptide Receptor 2 (VIP Receptor 2, VIP2R, VIPR2, Helodermin Preferring VIP Receptor, Helodermin-preferring VIP Receptor, Pituitary Adenylate Cyclase Activating Polypeptide Type III Receptor, PACAP Type III Receptor, VPAC2, VPAC2 Receptor)

Vasoactive intestinal peptide (VIP) is a 28-aminoacid peptide (human, chr 6q26-q27). Expressed and secreted by neurons innervating primary and secondary immune organs such as lymph nodes with a Mol.wt of 20kD. VIP is a potent neurotrophic factor causes vasodilation, lowers arterial blood pressure, and relaxes the smooth muscle of trachea, stomach and gall bladder. VIP also modulates several T-lymphocyte activities including motility, cytokine production, proliferation and apoptosis, VIP exerts its biological activity by binding to two closely related class II G-protein-coupled receptors VPAC-1 and VPAC-2 beside this VIP has its own receptors VIPR1&2 (Vasoactive Intestinal Polypeptide Receptor 1&2) and VIPRRP (VIP receptor-gene repressor protein). VIP shows similarities to glucagon, secretin and gastric inhibitory peptide (GIP) as such it has been considered a member of the glucagon-secretin family. The VIP is 100% conserved in mouse, rat and human. VIP is considered to be a viable candidate for the development of treatments for rheumatoid arthritis, since treatment with VIP significantly reduced incidence of severity of arthritis, the therapeutic effect of VIP was associated with downregulation of both inflammatory and autoimmune components of the disease. VIPR2, a 438aa (chr.7q36.3) protein in human (437aa in rat and mouse). The VIP receptor2 is also termed as type III PACAP receptor, mainly expressed in neural tissues. This is a receptor for VIP as well as PACAP 38 and 27, G proteins mediate the activity of this receptor, which activates adenyl cyclase and can be coupled to phospholipase C. It shows 86% sequence homology with rat VIPR2.

Applications
Suitable for use in ELISA. Western Blot, though not tested, may potentially be used as an application. Other applications not tested.
Recommended Dilution
ELISA: 0.5-1ug/ml; Control peptide can be used to coat ELISA plates at 1ug/ml. See V2115-26B. Western Blot: 1-10ug/ml; Using ECL technique. Optimal dilutions to be determined by the researcher.
Storage and Stability
Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with sterile ddH2O or PBS. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Reconstituted product is stable for 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
Immunogen
19aa peptide from rat VIPR2. Location: ~N-terminus, Extracellular domain. No significant homology is observed with VIPR1. Species Sequence Homology: Mouse - 94%; Human - 86%.
Form
Supplied as a lyophilized powder from PBS, 0.05% sodium azide.
Purity
Purified by immunoaffinity chromatography.
Specificity
Recognizes rat Vasoactive Intestinal Peptide Receptor 2.

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.

References
1. Lin Pei (1998), JBC,273, 19902-19908|2. Lin Pei (2000) JBC, 275, 1176-1182.|3. Bodner,M (1985) PNA,82, 3548-3551|4. Delgado, M (2001) Nature Med, 7, 563-568|5. Gotoh, E.(1998) Biochem. Int, 17, 555-562
USBio References
No references available
United States Biological | 4 Technology Way | Salem, MA 01970
Phone 800-520-3011 | Fax 978-594-8052 | Website www.usbio.net